These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2669130)

  • 81. Radiopharmaceuticals for thrombus detection.
    Knight LC
    Semin Nucl Med; 1990 Jan; 20(1):52-67. PubMed ID: 2136960
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Platelet surface IgG in patients receiving infusions of Fab fragments of a chimaeric monoclonal antibody to glycoprotein IIb-IIIa.
    Christopoulos C
    Clin Exp Immunol; 1994 Oct; 98(1):6-11. PubMed ID: 7923885
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".
    Reverter JC; Béguin S; Kessels H; Kumar R; Hemker HC; Coller BS
    J Clin Invest; 1996 Aug; 98(3):863-74. PubMed ID: 8698879
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Characterization of an anti-thrombospondin monoclonal antibody (P8) that inhibits human blood platelet functions. Normal binding of P8 to thrombin-activated Glanzmann thrombasthenic platelets.
    Boukerche H; McGregor JL
    Eur J Biochem; 1988 Jan; 171(1-2):383-92. PubMed ID: 3338471
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Formulation development of an antifibrin monoclonal antibody radiopharmaceutical.
    Kamat MS; Tolman GL; Brown JM
    Pharm Biotechnol; 1996; 9():343-64. PubMed ID: 8914198
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Cardiovascular applications: current status of immunoscintigraphy in the detection of myocardial necrosis using antimyosin (R11D10) and deep venous thrombosis using antifibrin (T2G1s).
    Manspeaker P; Weisman HF; Schaible TF
    Semin Nucl Med; 1993 Apr; 23(2):133-47. PubMed ID: 8511600
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Correlating labeling chemistry and in-vitro test results with the biological behavior of radiolabeled proteins.
    Srivastava SC; Meinken GE
    Int J Biol Markers; 1986; 1(3):111-20. PubMed ID: 3429946
    [TBL] [Abstract][Full Text] [Related]  

  • 88. A new method for protein labeling with 99mTc.
    Blok D; Feitsma RI; Wasser MN; Nieuwenhuizen W; Pauwels EK
    Int J Rad Appl Instrum B; 1989; 16(1):11-6. PubMed ID: 2714995
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A new method for labelling of monoclonal antibodies and their fragments with technetium-99m.
    Joiris E; Bastin B; Thornback JR
    Int J Rad Appl Instrum B; 1991; 18(3):353-6. PubMed ID: 2071447
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Current status of radionuclide tracer imaging of thrombi and atheroma.
    Cerqueira MD
    Semin Nucl Med; 1999 Oct; 29(4):339-51. PubMed ID: 10534236
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Platelet specific monoclonal antibody.
    Rhys Davies E
    Br J Radiol; 1990 Jun; 63(750):501. PubMed ID: 2379078
    [No Abstract]   [Full Text] [Related]  

  • 92. Kinetics of technetium-labeled heparin in thromboembolism: preliminary report.
    Esquerré JP; Boneu B; Guiraud R
    Int J Nucl Med Biol; 1979; 6(4):215-20. PubMed ID: 528149
    [No Abstract]   [Full Text] [Related]  

  • 93. Non-tumor applications of radioimmune imaging.
    Strauss HW; Fischman AJ; Khaw BA; Rubin RH
    Int J Rad Appl Instrum B; 1991; 18(1):127-34. PubMed ID: 2010297
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Antibody radiolabeling, problems and promises.
    Hnatowich DJ
    Int J Rad Appl Instrum B; 1990; 17(1):49-55. PubMed ID: 2407692
    [No Abstract]   [Full Text] [Related]  

  • 95. Radiolabeled blood cells: perspectives and directions.
    Thakur ML
    Int J Rad Appl Instrum B; 1990; 17(1):41-7. PubMed ID: 2407691
    [No Abstract]   [Full Text] [Related]  

  • 96. [131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity.
    Zanzonico P; Koehne G; Gallardo HF; Doubrovin M; Doubrovina E; Finn R; Blasberg RG; Riviere I; O'Reilly RJ; Sadelain M; Larson SM
    Eur J Nucl Med Mol Imaging; 2006 Sep; 33(9):988-97. PubMed ID: 16607546
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab'.
    Macfarlane DJ; Smart RC; Tsui WW; Gerometta M; Eisenberg PR; Scott AM
    Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):648-56. PubMed ID: 16528525
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Does immunoscintigraphy serve clinical needs effectively? Is there a future for radioimmunotherapy?
    Chatal JF; Peltier P; Bardiès M; Chétanneau A; Thedrez P; Faivre-Chauvet A; Gestin JF
    Eur J Nucl Med; 1992; 19(3):205-13. PubMed ID: 1572386
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Current status of immunoscintigraphy in the detection of thrombosis and thromboembolism.
    Koblik PD; De Nardo GL; Berger HJ
    Semin Nucl Med; 1989 Jul; 19(3):221-37. PubMed ID: 2669130
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Imaging arterial thrombosis: comparison of technetium-99m-labeled monoclonal antifibrin antibodies and indium-111-platelets.
    Stratton JR; Cerqueira MD; Dewhurst TA; Kohler TR
    J Nucl Med; 1994 Nov; 35(11):1731-7. PubMed ID: 7965148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.